Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Who Gets Pemphigus and Why?
Description
The discussion revolves around Pemphigus vulgaris (PV), an autoimmune blistering disorder, focusing on its etiology and pathogenesis. The traditional understanding posits that autoantibodies against desmogleins disrupt cell adhesion in the epidermis, leading to blisters. However, recent findings indicate a more complex interplay involving genetic factors. Studies have revealed a strong genetic predisposition, particularly with the ST18 gene, which regulates inflammation and cell adhesion. Variants in ST18 are linked to a significantly higher risk of developing PV and associated with more severe disease manifestations. This overexpression of ST18 may contribute to the chronicity of PV by secreting pro-inflammatory cytokines, including TNF-alpha, which destabilizes cell adhesion further. Furthermore, a cyclic mechanism involving ST18, desmogleins, and the P53 transcription factor perpetuates disease severity. P53 is shown to influence both ST18 expression and desmoglein levels, aiding in the maintenance of a chronic immune response. These insights suggest novel therapeutic approaches targeting these genetic and immunological factors, highlighting the potential for new treatments that could disrupt the vicious cycle of Pemphigus vulgaris and improve patient outcomes.
View moreConclusions
- Pemphigus vulgaris results from the negative effects of autoantibodies on cell-to-cell adhesion in the epidermis.
- Autoantibodies against desmoglein 3 are primarily responsible for causing blisters in pemphigus vulgaris.
- Recent research highlights the involvement of genetic factors in determining who develops pemphigus vulgaris.
- Variants in the ST18 gene are associated with an increased risk and severity of pemphigus vulgaris, particularly in Middle Eastern populations.
- The expression of ST18 promotes the production of pro-inflammatory cytokines, contributing to disease pathology.
- Disease chronicity may be explained by a feedback loop involving ST18, desmoglein 3, and p53, perpetuating cell disadhesion.
- New therapeutic approaches could target the ST18 signaling pathway or pro-inflammatory cytokines to manage pemphigus vulgaris.
- Sielski et al, Front Immunol, 2022
- Tam et al, Nat Rev Genet, 2019
- Saha et al, JID, 2010
- Abida et al, BJD, 2009
- Slomov et al, Hum Immunol, 2005
- Dalla-Costa et al, Hum Immunol, 2010
- Malheiros et al, G&I, 2009
- Mosaad et al, Hum Immunol, 2012
- Camargo et al, Hum Genet, 2016
- Cipolla et al, Biochim Biophys Acta, 2016
- Augusto et al, Eur J Immunol, 2015
- Chatzikyriakidou et al, Exp Dermatol, 2019
- Ben Jmaa et al, Immunol Lett, 2017
- Bumiller et al, Front Immunol, 2018
- Recke et al, Front Immunol, 2018
- Farias et al, Immunol, 2019
- Sarig et al, J Invest Dermatol, 2012
- Henry et al, J Biol Chem, 2014
- Yang et al, FASEB J, 2008
- Assaf et al, Br J Dermatol, 2021
- Malovitski et al, Loss-of-function variants in KLF4 underlie autosomal dominant palmoplantar keratoderma. Genet Med, in press, 2022